GEN
Gen Digital Inc.
GEN's outlook is improving, though it still trails on the overall score.
NVDA
NVIDIA Corporation
NVDA has the edge over GEN overall, supported by stronger valuation and stronger modeled upside.
GEN Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Strong | |
| Stable |
GEN's profitability and cash flow are currently strong, and its revenue and balance sheet are stable.
NVDA Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
NVDA's revenue, profitability, cash flow and balance sheet are all currently strong.
GEN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 8.3x | $16.34 | -45% |
| Forward | 9.5x | $29.69 | — |
| Current | 15x | $29.69 | — |
| Fair | 18x | $35.76 | +20% |
| Expensive | 28x | $54.70 | +84% |
Historical ranges are pointers, not guarantees.
GEN's PE is in its cheap range at 15x. If earnings grow as analysts expect, today's price would be 9.5x next year's earnings.
NVDA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $166 | — |
| Current | 21x | $166 | — |
| Cheap | 44x | $345 | +108% |
| Fair | 65x | $511 | +207% |
| Expensive | 93x | $734 | +342% |
Historical ranges are pointers, not guarantees.
NVDA has the edge over GEN in the historical PE scenario, which offers more potential upside but is not a forecast.
GEN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
GEN has the edge over NVDA on the outlook, with more favorable profitability expectations.
NVDA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Weakening | |
| Broad | |
| Moderate |
Analysts expect strong earnings and revenue growth for NVDA, but weaker profitability.
GEN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.12 | +58% |
| Q3 2026 | $1.98 | +118% |
| Q2 2026 | $1.71 | +78% |
| Q1 2026 | $1.57 | +52% |
| Q4 2025 | $0.96 | -6.8% |
| Q3 2025 | $0.91 | -8.1% |
| Q2 2025 | $0.96 | 0% |
| Q1 2025 | $1.03 | +7.3% |
| Q4 2024 | $1.03 | -53% |
GEN's earnings per share have fallen from their peak: $1.98 over the past year, against $6.20 in mid-2020.
NVDA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $13.77 | +74% |
| Q3 2026 | $7.91 | +125% |
| Q2 2026 | $6.53 | +111% |
| Q1 2026 | $4.90 | +67% |
| Q4 2025 | $4.03 | +59% |
| Q3 2025 | $3.51 | +65% |
| Q2 2025 | $3.10 | +81% |
| Q1 2025 | $2.94 | +147% |
| Q4 2024 | $2.54 | +234% |
NVDA has the edge over GEN on earnings, with more consistent year-over-year improvement.
GEN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.4B | +12% |
| Q2 2026 | $1.3B | +6.3% |
| Q1 2026 | $1.3B | +27% |
| Q4 2025 | $1.2B | +26% |
| Q3 2025 | $1.2B | +25% |
| Q2 2025 | $1.3B | +30% |
| Q1 2025 | $1B | +4.4% |
| Q4 2024 | $986M | +3.7% |
GEN's revenue has grown year over year every quarter since early 2021: $1.4B last quarter, up 12% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 37% | +1.1 points |
| Q2 2026 | 33% | -2.3 points |
| Q1 2026 | 63% | +21 points |
| Q4 2025 | 35% | -3 points |
| Q3 2025 | 36% | -5.4 points |
| Q2 2025 | 35% | -7.7 points |
| Q1 2025 | 41% | -0.1 points |
| Q4 2024 | 38% | +2.7 points |
GEN's operating margin was 37% last quarter, up 1.1 points from the same quarter a year ago.
NVDA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $96.2B | +106% |
| Q2 2026 | $81.6B | +85% |
| Q1 2026 | $68.1B | +73% |
| Q4 2025 | $57B | +62% |
| Q3 2025 | $46.7B | +56% |
| Q2 2025 | $44.1B | +69% |
| Q1 2025 | $39.3B | +78% |
| Q4 2024 | $35.1B | +94% |
NVDA has the edge over GEN on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 66% | +5.4 points |
| Q2 2026 | 66% | +17 points |
| Q1 2026 | 65% | +3.9 points |
| Q4 2025 | 63% | +0.8 points |
| Q3 2025 | 61% | -1.2 points |
| Q2 2025 | 49% | -16 points |
| Q1 2025 | 61% | -0.5 points |
| Q4 2024 | 62% | +4.9 points |
NVDA has the edge over GEN on profitability, with a higher operating margin.
GEN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $323M | +202% |
| Q2 2026 | $430M | +6.2% |
| Q1 2026 | $476M | +1.3% |
| Q4 2025 | $535M | +68% |
| Q3 2025 | $107M | -31% |
| Q2 2025 | $405M | +55% |
| Q1 2025 | $470M | -66% |
| Q4 2024 | $318M | +3.6% |
GEN generated $1.8B in free cash flow over the past year, up 36% from the year before.
NVDA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $21.4B | +59% |
| Q2 2026 | $48.6B | +86% |
| Q1 2026 | $34.9B | +124% |
| Q4 2025 | $22.1B | +32% |
| Q3 2025 | $13.5B | -0.3% |
| Q2 2025 | $26.2B | +75% |
| Q1 2025 | $15.6B | +38% |
| Q3 2024 | $13.5B | +113% |
NVDA has the edge over GEN on cash flow, with more consistent year-over-year improvement.
GEN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| 1 year | -3.4% | -21M shares |
| 3 years | -6.4% | -41M shares |
| 5 years | +2% | +12M shares |
| Available history | -6.8% | -44M shares |
GEN has the edge over NVDA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $171M |
| Q2 2026 | $100M |
| Q1 2026 | $200M |
| Q4 2025 | $300M |
| Q3 2025 | — |
| Q2 2025 | $134M |
| Q1 2025 | — |
| Q4 2024 | — |
GEN spent $771M buying back its own shares over the past year, about six times what it spent the year before.
NVDA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -106M shares |
| 1 year | -1% | -247M shares |
| 3 years | -2.8% | -705M shares |
| 5 years | -4.1% | -1B shares |
| Available history | -1.8% | -435M shares |
NVDA has 24.3B diluted shares, down 1% from a year ago, with $55.3B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $19.7B |
| Q2 2026 | $19.3B |
| Q1 2026 | $3.8B |
| Q4 2025 | $12.5B |
| Q3 2025 | $9.7B |
| Q2 2025 | $14.1B |
| Q1 2025 | $7.8B |
| Q4 2024 | $11B |
NVDA spent $55.3B buying back its own shares over the past year, up 30% from the year before.
GEN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.9x | Moderate |
| Q2 2026 | 3.0x | Moderate |
| Q1 2026 | 3.0x | Elevated |
| Q4 2025 | 3.7x | Elevated |
| Q3 2025 | 3.9x | Elevated |
| Q2 2025 | 4.1x | High |
| Q1 2025 | 3.6x | Elevated |
| Q4 2024 | 3.8x | Elevated |
GEN's net debt is about 2.9 years of its operating earnings (EBITDA), down from 3.9 years a year ago.
NVDA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.1x | Very low |
| Q2 2026 | -0.0x | Net Cash |
| Q1 2026 | -0.0x | Net Cash |
| Q4 2025 | -0.0x | Net Cash |
| Q3 2025 | -0.0x | Net Cash |
| Q2 2025 | -0.1x | Net Cash |
| Q1 2025 | -0.0x | Very low |
| Q4 2024 | -0.0x | Net Cash |
NVDA has the edge over GEN on leverage, with a lower net debt burden relative to earnings.
GEN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 59.3 | Neutral |
| Stochastic | 81.3 | Overbought |
GEN's weekly RSI is 59 (neutral) and its Stochastic is 81 (overbought).
NVDA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.4 | Neutral |
| Stochastic | 18.1 | Oversold |
NVDA's weekly RSI is 33 (neutral) and its Stochastic is 18 (oversold).
GEN PE vs Technology Sector
| Metric | GEN | Sector median | Relative |
|---|---|---|---|
| PE | 15x | 28x | 46% below |
| PE % | 32 | 35 | 3 pts below |
GEN has the edge over NVDA on valuation relative to its sector.
NVDA PE vs Technology Sector
| Metric | NVDA | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 28x | 25% below |
| PE % | 0 | 35 | 35 pts below |
NVDA is trading at 21x earnings, a 25% discount to the Technology sector's median of 28x.
GEN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $25.6 | 16% above |
| 20 week MA | $27.2 | 9% above |
| 50 week MA | $25.0 | 19% above |
| 100 week MA | $26.4 | 12% above |
| 200 week MA | $24.2 | 23% above |
GEN has the edge over NVDA on trend strength, trading above more of its moving averages.
NVDA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $208.9 | 20% below |
| 20 week MA | $212.0 | 22% below |
| 50 week MA | $199.9 | 17% below |
| 100 week MA | $175.1 | 5.1% below |
| 200 week MA | $123.6 | 34% above |
NVDA has fallen below most of its moving averages, though it's still 34% above its 200-week average.
GEN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $25.6 | $21.0 | -18% |
| 2021 | $21.0 | $25.9 | +23% |
| 2022 | $25.9 | $21.3 | -18% |
| 2023 | $21.3 | $22.8 | +7.1% |
| 2024 | $22.8 | $27.7 | +21% |
| 2025 | $27.7 | $27.8 | +0.4% |
| 2026 YTD | $27.8 | $29.7 | +6.9% |
GEN has the edge over NVDA on returns for 2026, with the stronger performance.
NVDA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.92 | $13.0 | +119% |
| 2021 | $13.0 | $29.6 | +128% |
| 2022 | $29.6 | $15.2 | -49% |
| 2023 | $15.2 | $49.5 | +226% |
| 2024 | $49.5 | $137.0 | +177% |
| 2025 | $137.0 | $190.5 | +39% |
| 2026 YTD | $190.5 | $166.2 | -13% |
NVDA's yearly returns have swung widely, from +226% in 2023 to −49% in 2022. It's down 13% so far in 2026.